Processa Pharmaceuticals, Inc.
PCSA
$0.2294
-$0.0059-2.51%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -6.55% | 46.95% | 60.17% | 65.18% | 59.45% |
| Total Depreciation and Amortization | 250.00% | -99.75% | -99.90% | -99.95% | -99.97% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -70.78% | -93.33% | -94.75% | -94.36% | -85.02% |
| Change in Net Operating Assets | -118.57% | -150.42% | -41.35% | 110.84% | 11.35% |
| Cash from Operations | -39.46% | -31.82% | 3.84% | 19.34% | 16.05% |
| Capital Expenditure | -14.29% | -14.29% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -14.29% | -14.29% | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 22.21% | 13.56% | -1.10% | -1.10% | -- |
| Repurchase of Common Stock | 70.59% | 61.27% | -16.89% | -14.64% | 78.58% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 23.36% | 14.56% | -1.39% | -1.33% | 1,712.35% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -95.54% | -80.91% | 8.30% | 50.14% | 82.01% |